Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) saw unusually-strong trading volume on Wednesday . Approximately 971,999 shares traded hands during trading, an increase of 394% from the previous session’s volume of 196,748 shares.The stock last traded at $1.50 and had previously closed at $1.36.

A number of analysts recently commented on CATB shares. HC Wainwright increased their price target on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research downgraded Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 19th. Wedbush reaffirmed an “ourperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a research report on Monday, May 15th. Finally, Oppenheimer Holdings, Inc. decreased their price target on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $4.50.

The stock’s market capitalization is $33.72 million. The stock has a 50 day moving average price of $1.26 and a 200-day moving average price of $1.35.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. On average, analysts predict that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Virtu KCG Holdings LLC purchased a new stake in Catabasis Pharmaceuticals during the 2nd quarter valued at $271,000. Oppenheimer & Co. Inc. raised its stake in Catabasis Pharmaceuticals by 33.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 30,000 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Catabasis Pharmaceuticals during the 1st quarter valued at $106,000. Institutional investors and hedge funds own 32.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Catabasis Pharmaceuticals, Inc. (CATB) Sees Large Volume Increase” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/06/catabasis-pharmaceuticals-inc-catb-sees-large-volume-increase-2.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.